Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study
| Autor: | Manuel Pabón-Carrasco, Raúl Martos-García, Samuel Vilar-Palomo, Aurora Castro-Méndez, Isabel Rodríguez-Gallego, Lucia Ramirez-Baena |
|---|---|
| Přispěvatelé: | Universidad de Sevilla. Departamento de Enfermería |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Crohn’s disease medicine.medical_specialty Efficacy efficacy MEDLINE lcsh:TX341-641 Disease Review Cochrane Library Inflammatory bowel disease 03 medical and health sciences 0302 clinical medicine inflammatory bowel disease Internal medicine medicine Humans ulcerative colitis Crohn's disease Nutrition and Dietetics business.industry Probiotics medicine.disease Inflammatory Bowel Diseases Ulcerative colitis Combined Modality Therapy Clinical trial Treatment Outcome probiotics 030220 oncology & carcinogenesis Relative risk 030211 gastroenterology & hepatology business lcsh:Nutrition. Foods and food supply Food Science |
| Zdroj: | idUS: Depósito de Investigación de la Universidad de Sevilla Universidad de Sevilla (US) idUS. Depósito de Investigación de la Universidad de Sevilla instname Nutrients Nutrients, Vol 12, Iss 2628, p 2628 (2020) |
| Popis: | (1) Background: Inflammatory bowel diseases are pathologies of unknown etiology and auto-immune pathogenia. The use of probiotics is studied in order to increase the arsenal of treatments. The aim was to assess the efficacy of the probiotics in these diseases in the active or quiescent phases; (2) Methods: A systematic review with meta-analysis was performed by an exhaustive bibliographic search in Medline, Cinahl, Embase, Scopus, Web of Science, and Cochrane Library. The inclusion criteria were studies of more than 10 years, English/Spanish, clinical trials, and involving human beings. Relative risk was used to compare efficacy, which was meta-analyzed using a fixed effects model. Heterogeneity was evaluated with the Higgins I2 test; (3) Results: Nineteen studies were included in the systematic review and 17 in the meta-analysis, with a total of 1537 patients (nexperimental group = 762; nplacebo group = 775). There are significant remission differences in ulcerative colitis (relative risk (RR) = 0.81; 95% CI = 0.72–0.91; I2 = 32%; p = 0.16). However, no significant differences were found in the use of probiotics for the prevention of ulcerative colitis, and for the remission of Crohn’s disease; (4) Conclusions: There are data showing an additional beneficial effect of probiotics on active ulcerative colitis. More and better studies are needed which assess its possible therapeutic efficacy for quiescent ulcerative colitis and for Crohn’s disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|